These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 21970134)

  • 1. Safety of exposure of malignant hyperthermia non-susceptible patients and their relatives to anaesthetic triggering agents.
    Pollock N; Langton EE; Stowell KM; Bulger TF
    Anaesth Intensive Care; 2011 Sep; 39(5):887-94. PubMed ID: 21970134
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Administration of anaesthetic triggering agents to patients tested malignant hyperthermia normal and their relatives in New Zealand: an update.
    Frei D; Stowell KM; Langton EE; McRedmond L; Pollock NA; Bulger TF
    Anaesth Intensive Care; 2017 Sep; 45(5):611-618. PubMed ID: 28911291
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suspected malignant hyperthermia reactions in New Zealand.
    Pollock AN; Langton EE; Couchman K; Stowell KM; Waddington M
    Anaesth Intensive Care; 2002 Aug; 30(4):453-61. PubMed ID: 12180584
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of anaesthesia in patients suspected to be susceptible to malignant hyperthermia before diagnostic in vitro contracture test.
    Bendixen D; Skovgaard LT; Ording H
    Acta Anaesthesiol Scand; 1997 Apr; 41(4):480-4. PubMed ID: 9150775
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safe duration of postoperative monitoring for malignant hyperthermia patients administered non-triggering anaesthesia: an update.
    Barnes C; Stowell KM; Bulger T; Langton E; Pollock N
    Anaesth Intensive Care; 2015 Jan; 43(1):98-104. PubMed ID: 25579296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evidence of malignant hyperthermia in patients administered triggering agents before malignant hyperthermia susceptibility identified: missed opportunities prior to diagnosis.
    Chan TY; Bulger TF; Stowell KM; Gillies RL; Langton EE; Street NE; Pollock NA
    Anaesth Intensive Care; 2017 Nov; 45(6):707-713. PubMed ID: 29137581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of anaesthesias in malignant hyperthermia negative patients.
    Islander G; Ranklev-Twetman E
    Acta Anaesthesiol Scand; 1995 Aug; 39(6):819-21. PubMed ID: 7484041
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Retrospective analysis of anaesthetics received by patients before susceptibility to malignant hyperpyrexia was recognized.
    Halsall PJ; Cain PA; Ellis FR
    Br J Anaesth; 1979 Oct; 51(10):949-54. PubMed ID: 518796
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Malignant hyperthermia and day stay surgery.
    Pollock N; Langton E; McDonnell N; Tiemessen J; Stowell K
    Anaesth Intensive Care; 2006 Feb; 34(1):40-5. PubMed ID: 16494148
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Follow-up of patients tested for malignant hyperthermia susceptibility.
    Scala D; Di Martino A; Cozzolino S; Mancini A; Bracco A; Andria B; Tammaro A; Savoia G
    Eur J Anaesthesiol; 2006 Sep; 23(9):801-5. PubMed ID: 16780615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Malignant hyperthermia deaths related to inadequate temperature monitoring, 2007-2012: a report from the North American malignant hyperthermia registry of the malignant hyperthermia association of the United States.
    Larach MG; Brandom BW; Allen GC; Gronert GA; Lehman EB
    Anesth Analg; 2014 Dec; 119(6):1359-66. PubMed ID: 25268394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incidence of malignant hyperthermia reactions in 2,214 patients undergoing muscle biopsy.
    Carr AS; Lerman J; Cunliffe M; McLeod ME; Britt BA
    Can J Anaesth; 1995 Apr; 42(4):281-6. PubMed ID: 7788824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safe duration of postoperative monitoring for malignant hyperthermia susceptible patients.
    Pollock N; Langtont E; Stowell K; Simpson C; McDonnell N
    Anaesth Intensive Care; 2004 Aug; 32(4):502-9. PubMed ID: 15675210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. McArdle's disease and anaesthesia: case reports. Review of potential problems and association with malignant hyperthermia.
    Bollig G; Mohr S; Raeder J
    Acta Anaesthesiol Scand; 2005 Sep; 49(8):1077-83. PubMed ID: 16095447
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Diagnosis of susceptibility for malignant hyperthermia using in-vitro muscle contraction testing in Switzerland].
    Urwyler A; Censier K; Seeberger MD; Drewe J; Rothenbühler JM; Frei F
    Schweiz Med Wochenschr; 1991 Apr; 121(16):566-71. PubMed ID: 2042040
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In-vitro contracture testing for susceptibility to malignant hyperthermia: can halothane be replaced?
    Metterlein T; Schuster F; Kranke P; Roewer N; Anetseder M
    Eur J Anaesthesiol; 2011 Apr; 28(4):251-5. PubMed ID: 20827211
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anesthetic Outcomes of Children With Arthrogryposis Syndromes: No Evidence of Hyperthermia.
    Gleich SJ; Tien M; Schroeder DR; Hanson AC; Flick R; Nemergut ME
    Anesth Analg; 2017 Mar; 124(3):908-914. PubMed ID: 28099287
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple anaesthetics for a malignant hyperthermia susceptible patient.
    Emmanuel ER
    Anaesthesia; 1988 Aug; 43(8):666-70. PubMed ID: 3421459
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The changing face of malignant hyperthermia: less fulminant, more insidious.
    Heytens L; Forget P; Scholtès JL; Veyckemans F
    Anaesth Intensive Care; 2015 Jul; 43(4):506-11. PubMed ID: 26099765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anesthesia for patients with a history of malignant hyperthermia.
    Wappler F
    Curr Opin Anaesthesiol; 2010 Jun; 23(3):417-22. PubMed ID: 20173632
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.